Target Knowledge Gap: FTD Gap #7: "Why do some carriers of pathogenic GRN mutations remain asymptomatic into old age?" (Score: 31/40) — Resilience factors could reveal protective mechanisms applicable to all FTD forms.
Disease: Frontotemporal Dementia (FTD)
Priority Rank: 7 (Tier 1: Critical)
Penetrance of GRN mutations is incomplete — not all carriers develop FTD. Some individuals carrying pathogenic GRN mutations remain asymptomatic into their 80s or 90s. Understanding what protects these "resilient" carriers could:
- Reveal endogenous neuroprotective mechanisms applicable to all neurodegenerative diseases
- Identify novel therapeutic targets
- Guide timing of preventive interventions
- Inform TMEM106B biology and lysosomal dysfunction pathways
Resilience is multifactorial, likely involving:
- Genetic modifiers: TMEM106B haplotypes, SORT1, and other rare variants
- Compensatory progranulin expression: Alternative splicing or promoter usage — GRN has complex 5' UTR regulation
- Cellular stress resistance: Enhanced protein quality control, autophagy, lysosomal function
- Cognitive reserve: Greater neural reserve or compensation — neurogenesis, synaptic plasticity
- Immune modulation: Reduced neuroinflammation in resilient carriers — TREM2 variants may play a role
Case-control study comparing resilient GRN carriers vs affected carriers vs non-carrier controls
| Group |
Definition |
N |
| Resilient carriers |
GRN mutation carriers, age ≥70, asymptomatic |
50 |
| Affected carriers |
GRN mutation carriers, FTD diagnosed |
100 |
| At-risk carriers |
GRN mutation carriers, age <60, asymptomatic |
50 |
| Controls |
Non-carriers, matched for age/education |
100 |
- Source: ARTFL/LEFFTDS consortium, Genetic FTD Initiative (GENFI)
- Inclusion: Confirmed pathogenic GRN variant, comprehensive cognitive testing
| Assessment |
Purpose |
| Neurological exam |
Document current status |
| Neuropsychological battery |
Cognitive domain assessment |
| MRI with volumetry |
Brain structure, hippocampal volume |
| CSF biomarkers |
NfL, p-tau181, progranulin |
| PET imaging |
FDG-PET for network dysfunction |
-
Whole-genome sequencing:
- Identify genetic modifiers (TMEM106B, other rare variants)
- Polygenic risk score for FTD
-
RNA sequencing (blood):
- Gene expression signatures
- Immune cell activation patterns
-
Proteomics (CSF):
- Protein abundance differences
- Post-translational modifications
-
Epigenomics:
-
iPSC-derived neurons (resilient vs affected carriers):
- Compare neuronal survival under stress
- Measure progranulin expression levels
- Assess protein homeostasis capacity
-
Functional assays:
- Autophagy flux measurement
- Stress granule dynamics
- Mitochondrial function
- Genetic modifier identification: Common and rare variants associated with resilience — TMEM106B, SORT1, GBA variants among targets
- Biomarker panel for resilience: Blood/CSF signatures predicting resilience — NfL, p-tau181, progranulin levels, cytokine profiles
- Mechanistic pathway identification: How modifiers confer protection — lysosomal function, autophagy flux, protein homeostasis
- Risk prediction model: Age at onset prediction for pre-symptomatic carriers — integrate with neuroimaging (MRI, FDG-PET) and CSF biomarkers
This experiment connects to multiple neurodegenerative disease mechanisms:
| Dimension |
Score |
Rationale |
| Technical Feasibility |
9/10 |
Existing cohorts, standard techniques |
| Timeline |
24 months |
12 mo recruitment, 12 mo analysis |
| Cost |
$2M |
Cohort assessments ($800K), omics ($800K), iPSC ($400K) |
| Data Availability |
8/10 |
ARTFL, GENFI already have carrier data |
| Risk |
Likelihood |
Mitigation |
| Insufficient resilient carriers |
Medium |
Expand international collaboration |
| Survivor bias (only oldest carriers identified) |
High |
Also study carriers at different ages |
| Variable mutation types |
Medium |
Stratify by mutation type in analysis |
- GENFI: Primarily focused on affected carriers; this focuses on resilient
- TMEM106B studies: One known modifier; more likely exist
- AD resilience studies: Methodological framework adaptable to FTD
| Role |
Institution |
Expertise |
| Lead PI |
Mayo Clinic (Boeve) |
GRN natural history |
| Genetics |
UCSF (Boxer) |
FTD genetics |
| Biostatistics |
UPenn (Drayman) |
Resilience modeling |
| iPSC |
Cambridge (Isaacs) |
FTD iPSC models |
- Target identification: Pathways that confer resilience → drug targets
- Biomarker development: Predict which carriers will remain asymptomatic
- Timing guidance: When to intervene in pre-symptomatic carriers
- Boxer AL, et al, Advancing research and treatment for frontotemporal lobar degeneration (ARTFL) (2019)
- Finger EC, et al, Fluid biomarkers in frontotemporal dementia: past, present and future (2021)
- Rohrer JD, et al, The heritability and genetics of frontotemporal lobar degeneration (2009)